Matthew Coffey
PhD
Chief Executive Officer
👥Biography 个人简介
Matthew Coffey has led clinical development of pelareorep (reovirus) as a systemically administered oncolytic virus and demonstrated it can be delivered intravenously to reach tumors. His work identified RAS pathway activation as a determinant of reovirus replication selectivity, providing a mechanism-based rationale for use in RAS-mutant tumors. The BRACELET-1 trial in breast cancer demonstrated synergy with paclitaxel and atezolizumab.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Matthew Coffey 的研究动态
Follow Matthew Coffey's research updates
留下邮箱，当我们发布与 Matthew Coffey（Oncolytics Biotech）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment